Table 5.
All-grade AEs reported in >10% of patients and grade 3 to 5 AEs occurring in ≥5% of patients (N = 40)
| All-grade AE | n (%) | Grade 3-5 AE | n (%) |
|---|---|---|---|
| Hematologic toxicity | Hematologic toxicity | ||
| Neutropenia | 14 (35.0) | Neutropenia | 13 (32.5) |
| Febrile neutropenia | 4 (10.0) | ||
| Thrombocytopenia | 2 (5.0) | ||
| Anemia | 2 (5.0) | ||
| Nonhematologic toxicity | Nonhematologic toxicity | ||
| Infusion-related reaction | 27 (67.5) | Lipase increased | 12 (30.0) |
| Cough | 23 (57.5) | Pneumonia | 6 (15.0) |
| Fatigue | 22 (55.0) | Colitis | 2 (5.0) |
| Nausea | 20 (50.0) | Hepatitis | 2 (5.0) |
| Diarrhea | 19 (47.5) | Hyperglycemia | 2 (5.0) |
| Constipation | 17 (42.5) | Upper respiratory tract infection | 2 (5.0) |
| Headache | 17 (42.5) | ||
| Rash | 13 (32.5) | ||
| Upper respiratory tract infection | 13 (32.5) | ||
| Lipase increased | 12 (30.0) | ||
| Pruritus | 12 (30.0) | ||
| Pyrexia | 12 (30.0) | ||
| Back pain | 10 (25.0) | ||
| Chest pain | 10 (25.0) | ||
| Vomiting | 10 (25.0) | ||
| Arthralgia | 8 (20.0) | ||
| Oropharyngeal pain | 8 (20.0) | ||
| Pneumonia | 8 (20.0) | ||
| Abdominal pain | 7 (17.5) | ||
| Dyspepsia | 7 (17.5) | ||
| Dyspnea | 7 (17.5) | ||
| Influenza-like illness | 7 (17.5) | ||
| Nasal congestion | 7 (17.5) | ||
| Pain in extremity | 7 (17.5) | ||
| Sinusitis | 7 (17.5) | ||
| Urinary tract infection | 7 (17.5) | ||
| Upper abdominal pain | 6 (15.0) | ||
| Dizziness | 6 (15.0) | ||
| Hypertension | 6 (15.0) | ||
| Insomnia | 6 (15.0) | ||
| Anxiety | 5 (12.5) | ||
| Decreased appetite | 5 (12.5) | ||
AE, adverse event.